Trial suggests Covovax an effective alternative to mRNA booster
The Covovax vaccine can be an effective booster especially for people who have had two doses of Covid-19 vaccine developed using inactivated virus technology, says virologist Yong Poovorawan.
Dr Yong, head of the Center of Excellence in Clinical Virology at Chulalongkorn University, said Covovax's effectiveness as a booster, especially among those who had received two doses of inactivated virus vaccines, was confirmed by a lab test.
Inactivated virus vaccines include Sinovac and Sinopharm.
On April 21, the Indian Embassy in Thailand donated 200,000 Covovax doses to the government.
The jabs were paid for by members of the Quadrilateral Security Dialogue comprising Australia, India, Japan and the US.
The Center of Excellence in Clinical Virology has worked jointly with the Chon Buri Provincial Public Health Office to study the effectiveness of the Covovax vaccine.
An unofficial trial study has indicated that a Covovax booster dose worked best on participants who had two shots of Sinopharm vaccine and received a Covovax jab three months after.
Covovax is seen as an alternative to mRNA vaccines as a booster shot.